Furthermore, EGCG treatment counteracted the activated effects of the TGF/Smad, PI3K/Akt/FoxO1, and NF-κB signaling pathways to alter hepatic fibrosis in NAFLD models [179]. The gene discussed is NFKB1; the disease is Hepatic fibrosis.